SCM
KROS icon

Sterling Capital Management’s Keros Therapeutics KROS Stock Holding History

Sterling Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.99K Sell
373
-3,988
-91% -$44.4K ﹤0.01% 2739
2026
Q1 		$48.1K Sell
4,361
-2,663
-38% -$41.1K ﹤0.01% 1656
2025
Q4 		$143K Buy
7,024
+4,694
+201% +$82.4K ﹤0.01% 1407
2025
Q3 		$36.9K Buy
2,330
+1,418
+155% +$20.9K ﹤0.01% 1873
2025
Q2 		$12.2K Buy
912
+882
+2,940% +$11.9K ﹤0.01% 2005
2025
Q1 		$306 Hold
30
– – ﹤0.01% 3035
2024
Q4 		$475 Hold
30
– – ﹤0.01% 3040
2024
Q3 		$1.74K Buy
+30
New +$1.48K ﹤0.01% 2245

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Sterling Capital Management's KROS Position: Q2 2026 in Review

Sterling Capital Management reduced its Keros Therapeutics (KROS) stake by 91% in Q2 2026, selling an estimated $44.4K and leaving 373 shares worth $3.99K. The position accounts for ﹤0.01% of the portfolio, ranked #2739.

Sterling Capital Management first reported a position in KROS in Q3 2024 and has held it in 8 quarters since. The position peaked at $143K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Sterling Capital Management held 373 shares of Keros Therapeutics worth $3.99K as of Q2 2026.
  • Sterling Capital Management sold 3,988 Keros Therapeutics shares in Q2 2026, an estimated $44.4K.
  • Keros Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2739 holding.
  • Sterling Capital Management first reported a position in Keros Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Keros Therapeutics position peaked at $143K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.